After years of "post-pandemic hibernation" and a seemingly inexorable decline in research and development (R&D) efficiency, the global pharmaceutical industry has finally witnessed a meaningful uptick in productivity. According to the 16th edition of Deloitte’s annual Measuring the Return from Pharmaceutical Innovation report, the projected internal rate of return (IRR) on late-stage pipeline assets reached 7.0% in 2025, a significant climb from the 5.9% recorded in 2024.
While this data might suggest a long-awaited industry renaissance, the reality is far more nuanced. The 2025 report—appropriately titled Navigating the GLP-1 boom—reveals a sector riding a singular wave of success while simultaneously masking structural weaknesses in its broader research engine.
The Main Facts: A Mirage of Growth?
On the surface, the headline figure of 7.0% serves as a beacon of optimism for investors and stakeholders. It marks the third consecutive year of growth in IRR, a trend Kevin Dondarski, principal for life sciences strategy at Deloitte Consulting, describes as "analytically unprecedented." For decades, the industry grappled with shrinking returns, interrupted only by the brief, anomalous surge in productivity associated with COVID-19 vaccine development.
However, the report includes a cautionary "catch." The growth observed in 2025 is overwhelmingly tied to the explosive commercial success of GLP-1 and GIP receptor agonists, which have revolutionized the treatment of obesity and related metabolic conditions. These therapies currently account for an estimated 38% of all projected commercial inflows from the 2025 late-stage pipeline.
The mathematical reality is startling: if one were to strip the GLP-1/GIP class from the equation, the headline IRR would plummet from 7.0% to a mere 2.9%. This disparity highlights a stark divergence between the industry’s blockbuster-driven performance and its underlying, core pipeline productivity.
Chronology: The Evolution of the Obesity Boom
The journey to the current, hyper-concentrated landscape has been rapid, marked by several key milestones:
- Early 2020s: The biopharma industry struggled with clinical trial attrition and rising costs, leading to a decade-long stagnation in R&D returns.
- 2023–2024: The widespread adoption of GLP-1 agonists began to reshape the metabolic disease market, driving record-breaking sales for pioneers like Eli Lilly and Novo Nordisk.
- November 2025: Novo Nordisk underwent a massive structural reorganization, including the departure of seven board members and the announcement of a 9,000-role workforce reduction, signaling that even industry leaders were struggling to balance rapid growth with operational efficiency.
- February 2026: The failure of Novo’s CagriSema to show non-inferiority against Eli Lilly’s Zepbound in the REDEFINE 4 trial served as a sobering reminder of the high-stakes, "winner-take-most" nature of the current R&D environment.
- April 2026: Eli Lilly launched its oral GLP-1, Foundayo (orforglipron), further solidifying its dominant position in the metabolic space, even as the company’s stock price faced year-to-date pressure.
- May 2026: The release of the 16th Deloitte report confirmed that obesity-related therapies had officially displaced oncology as the largest share of late-stage pipeline value, capturing 24.7% of the total.
Supporting Data: The Hidden Erosion of Productivity
While the "GLP-1 boom" has captured the imagination of the market, the underlying metrics of R&D health tell a story of escalating costs and waning sustainability.
The Cost of Innovation
The average cost to shepherd a drug from initial discovery to market launch hit a record $2.67 billion in 2025, up from $2.23 billion the previous year. Deloitte’s data shows that this trend is not limited to a few outliers; 17 of the 20 companies surveyed reported significant increases in development costs. This trend is driven by three converging factors:
- Inflationary Pressures: R&D expenditures are consistently outpacing general inflation.
- M&A Bloat: Large-scale mergers and acquisitions are inflating the R&D cost base without necessarily yielding proportional increases in successful outputs.
- Attrition: A 4–5% decline in the number of late-stage programs suggests that despite the high spending, the industry is struggling to maintain a robust, diversified pipeline.
The Peak Sales Spread
The report’s data on "average forecast peak sales" further underscores the reliance on blockbuster classes. While the average hit $598 million per asset, the "without GLP-1s/GIPs" marker dropped to $353 million—a lower figure than the previous year. This indicates that for the vast majority of non-obesity assets, productivity is not merely plateauing; it is actively declining.
Official Responses and Strategic Implications
The industry is currently grappling with the responsibility of "replacing the golden goose." As Dondarski noted, the concentration of value within the GLP-1 class is the most dramatic in the history of Deloitte’s reporting.
Sustainability and Market Pressure
Investors are increasingly skeptical about the long-term durability of the obesity boom. Even as Eli Lilly raised its full-year revenue guidance to $82–$85 billion, its share price has faced volatility, reflecting a market that is pricing in both the immense success of current products and the uncertainty of future pipeline growth. Similarly, Novo Nordisk’s massive restructuring efforts illustrate the internal friction created by the need to sustain growth in a saturated, highly competitive market.
The Pricing Headwind
The competitive landscape is further complicated by regulatory and political shifts. The recent agreement by major players to lower U.S. prices for GLP-1s via Medicare, Medicaid, and the "TrumpRx" initiative has placed downward pressure on realized pricing. Lilly’s Q1 2026 earnings, for instance, showed a 56% revenue increase, but this was significantly tempered by a 13% decline in realized prices, highlighting that volume growth alone cannot offset pricing erosion indefinitely.
The AI Dilemma: Still Waiting for Liftoff
Perhaps the most significant finding in the report for the future of the industry is the failure of Artificial Intelligence (AI) to yield the promised efficiencies. Despite last year’s rallying cry to "Be brave, be bold" and invest in AI-powered drug discovery, clinical cycle times remain stubbornly long.
The report concedes that the promise of AI—specifically its potential to slash development times and costs—has yet to be realized at scale. This failure is largely attributed to a "pilot-driven, function-by-function" approach. While pharmaceutical companies have embraced AI for specific, isolated tasks, they have failed to integrate these tools into an end-to-end development architecture.
"Everybody is actively focusing on AI, and everybody has had some degree of success," Dondarski explained. "But from our vantage point, there is a good amount of variability in the velocity at which organizations are scaling those efforts to maximize value creation."
Conclusion: A Turning Point for Big Pharma
The 2025 landscape, as documented by Deloitte, presents a classic paradox of modern medicine: the industry is more profitable than it has been in years, yet its underlying business model is more fragile than ever. By allowing a single therapeutic class to account for the vast majority of its value, the sector has created an "obesity-or-bust" environment.
For pharmaceutical leaders, the path forward requires a two-pronged approach. First, they must address the unsustainable rise in R&D costs by moving beyond fragmented AI pilots and toward true operational integration. Second, they must diversify their pipelines to ensure that the current boom in metabolic medicine serves as a foundation for future innovation, rather than a temporary crutch that masks a broader decline in scientific productivity.
As the industry moves into the latter half of the decade, the question is no longer whether they can innovate, but whether they can sustain that innovation across a broader, more diverse, and more cost-effective landscape. For now, the "GLP-1 spring" is in full bloom, but the shadows of rising costs and declining core productivity remain long, waiting for the next generation of leadership to address the systemic challenges ahead.
About the Author
